MAIA Biotechnology, Inc. (MAIA)
| Market Cap | 48.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.25M |
| Shares Out | 29.59M |
| EPS (ttm) | -1.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,900 |
| Open | 1.620 |
| Previous Close | 1.650 |
| Day's Range | 1.610 - 1.670 |
| 52-Week Range | 1.460 - 5.990 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 21, 2025 |
About MAIA
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois. [Read more]
Financial Performance
Financial StatementsNews
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025.
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug.
MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO.
MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
CHICAGO--(BUSINESS WIRE)--MAIA to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced NSCLC Patients.
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA,” the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today anno...
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million.
MAIA Biotechnology Announces Private Placement of $2,715,000
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Private Placement of $2,715,000.
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer.
MAIA Biotechnology to Present at Biotech Showcase 2025
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Biotech Showcase 2025.
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings.
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas.
MAIA Biotechnology Announces Private Placement of Approximately $950,000
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Private Placement of Approximately $950,000.
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer.
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement.
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the SITC 39th Annual Meeting.
MAIA Biotechnology Announces $2.44 Million Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $2.44 Million Private Placement.
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics.
MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer.
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference.
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
On Tuesday, MAIA Biotechnology Inc MAIA announced treatment updates from its Phase 2 THIO-101 trial of THIO sequenced with Regeneron Pharmaceuticals Inc's REGN cemiplimab (Libtayo) for advanced non-sm...
MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent.
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy.
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent.
MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer.
MAIA Biotechnology to Present at the BIO International Convention 2024
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at the BIO International Convention 2024.